(MedPage Today) — CHICAGO — The bispecific T-cell engager tarlatamab (Imdelltra) significantly prolonged survival in the second-line treatment of small cell lung cancer (SCLC), a practice-changing phase III trial showed.
In patients whose…
Source link : https://www.medpagetoday.com/meetingcoverage/asco/115891
Author :
Publish date : 2025-06-03 21:16:00
Copyright for syndicated content belongs to the linked Source.
